Patents by Inventor Kevin McDonnell

Kevin McDonnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220242911
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Application
    Filed: February 4, 2022
    Publication date: August 4, 2022
    Inventors: Gemma MUDD, Punit UPADHYAYA, Kevin MCDONNELL, Johanna LAHDENRANTA
  • Patent number: 11396530
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: July 26, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20220227811
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Application
    Filed: February 2, 2022
    Publication date: July 21, 2022
    Inventors: Gemma MUDD, Punit UPADHYAYA, Kevin MCDONNELL, Johanna LAHDENRANTA
  • Publication number: 20220213145
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Application
    Filed: January 21, 2022
    Publication date: July 7, 2022
    Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma Elizabeth MUDD, Peter PARK
  • Publication number: 20220194983
    Abstract: A peptide ligand specific for prostate specific membrane antigen (PSMA) comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold.
    Type: Application
    Filed: June 19, 2019
    Publication date: June 23, 2022
    Inventors: Daniel TEUFEL, Gemma MUDD, Silvia PAVAN, Kevin MCDONNELL, Punit UPADHYAYA
  • Patent number: 11332500
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 17, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell
  • Patent number: 11312749
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: April 26, 2022
    Assignee: BicycleTx Limited
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Patent number: 11306123
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Grant
    Filed: July 29, 2020
    Date of Patent: April 19, 2022
    Assignee: BICYCLETX LIMITED
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Publication number: 20220088207
    Abstract: The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.
    Type: Application
    Filed: December 23, 2019
    Publication date: March 24, 2022
    Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
  • Patent number: 11261214
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: March 1, 2022
    Assignee: BicycleTx Limited
    Inventors: Liuhong Chen, Rachid Lani, Kevin McDonnell, Gemma Mudd, Peter Park
  • Publication number: 20220031858
    Abstract: The invention relates to novel linkers which comprise two or three basic, acidic or hydrophobic natural or non-natural amino acids. The invention also relates to drug conjugates comprising said linkers, to pharmaceutical compositions comprising said drug conjugates and to the use of said drug conjugates in preventing, suppressing or treating cancer.
    Type: Application
    Filed: August 3, 2021
    Publication date: February 3, 2022
    Inventors: Kevin MCDONNELL, Gemma MUDD, Paul John Beswick
  • Patent number: 11215257
    Abstract: A shock absorbing system for impact energy dissipation employs removable unitary cells of compressible members in communication with a reservoir and containing a first working fluid. Resilient structural members may be placed intermediate the compressible members to deform responsive to compression to provide both energy dissipation and resilient recovery of the compression cylinders to their uncompressed state.
    Type: Grant
    Filed: December 16, 2018
    Date of Patent: January 4, 2022
    Inventor: Kevin McDonnell
  • Publication number: 20210299210
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on an immune cell, conjugated via a linker to a second peptide ligand, which binds to a component present on a cancer cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Application
    Filed: April 2, 2019
    Publication date: September 30, 2021
    Inventors: Nicholas Keen, Kevin McDonnell, Peter Park, Punit Upadhyaya
  • Publication number: 20210147484
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 20, 2021
    Inventors: Paul BESWICK, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20210101932
    Abstract: The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 8, 2021
    Inventors: Liuhong CHEN, James COOKE, Kevin MCDONNELL, Gemma MUDD, Katerine VAN RIETSCHOTEN, Punit UPADHYAYA
  • Publication number: 20210101933
    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.
    Type: Application
    Filed: October 26, 2020
    Publication date: April 8, 2021
    Inventors: Liuhong CHEN, Rachid LANI, Kevin MCDONNELL, Gemma MUDD, Peter U. PARK, Punit UPADHYAYA
  • Publication number: 20210101937
    Abstract: The present invention relates to heterotandem bicyclic peptide complexes which comprise a first peptide ligand, which binds to a component present on a cancer cell, conjugated via a linker to a second peptide ligand, which binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in preventing, suppressing or treating cancer.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Gemma MUDD, Punit Upadhyaya, Kevin McDonnell
  • Publication number: 20210069287
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Application
    Filed: July 29, 2020
    Publication date: March 11, 2021
    Inventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
  • Patent number: 10919937
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 16, 2021
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20210040154
    Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to Nectin-4, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.
    Type: Application
    Filed: July 29, 2020
    Publication date: February 11, 2021
    Inventors: Gemma MUDD, Punit UPADHYAYA, Kevin MCDONNELL, Johanna LAHDENRANTA